THE INFLUENCE OF GENE POLYMORPHISMS СУР2С19 ON THE EFFECTIVENESS OF ERADICATION THERAPY OF H. PYLORI
Abstract
The clinical situation in which the dependence of the result of Н. pylori eradication therapy on the genotype СYР2С19 controlling the metabolism rate of proton pump inhibitors is described. When carrying the allele variant СUR2С19 * 17 (homo-, heterozygote), a person refers to the “fast metabolizers” of this group of drugs. In view of this anti-Helicobacter therapy can not be achieved in the proper amount.
About the Authors
E. N. Bojko
“Russian Medical Academy of Continuing Professional Education” Russian Federation Ministry of Health
Russian Federation
Russian Federation
N. P. Denisenko
“Russian Medical Academy of Continuing Professional Education” Russian Federation Ministry of Health
Russian Federation
Russian Federation
E. A. Grishina
“Russian Medical Academy of Continuing Professional Education” Russian Federation Ministry of Health
Russian Federation
Russian Federation
K. A. Ryzhikova
“Russian Medical Academy of Continuing Professional Education” Russian Federation Ministry of Health
Russian Federation
Russian Federation
Zh. A. Sozaeva
“Russian Medical Academy of Continuing Professional Education” Russian Federation Ministry of Health
Russian Federation
Russian Federation
Zh. M. Sizova
First Moscow state medical University. I. M. Sechenov Russian Ministry Of Health
Russian Federation
Russian Federation
L. R. Panteleeva
First Moscow state medical University. I. M. Sechenov Russian Ministry Of Health
Russian Federation
Russian Federation
G. A. Belyakova
First Moscow state medical University. I. M. Sechenov Russian Ministry Of Health
Russian Federation
Russian Federation
D. A. Sychev
“Russian Medical Academy of Continuing Professional Education” Russian Federation Ministry of Health
Russian Federation
Russian Federation
References
1. И.В. Маев, Ю. А. Кучерявый, Д. Н. Андреев «Причины неэффективности антигеликобактерной терапии». РЖГК. -2013. - Т. 23. -№ 6. - с. 62-72
2. «Актуальные вопросы оказания медицинской помощи больным с кислотозависимыми заболеваниями в клинической практике». Медицинский алфавит № 19 (316) 2017. Практическая гастроэнтерология. - Том № 2. - стр. 11
3. Сычев Д.А. «Фармакогенетическое тестирование: клиническая интерпретация результатов»2011. стр.48
4. Malfertheiner P., Megraud F., O’Morain C.A. et al. Management of Helicobacter pylori infection - the Maastricht IV/ Florence Consensus Report // Gut. 2012. Vol. 61. № 5. P. 646-664
5. С. И. Пиманов, Е. В. Макаренко. Рекомендации Маастрихт V/Флорентийского консенсуса по лечению хеликобактерной инфекции. ConsiliumMedicum. 2017; 8.1: 8-27
6. Ивашкин В. Т., Маев И. В., Лапина Т. Л., Шептулин А. А., Трухманов А. С., Абдулхаков Р. А. и др. Лечение инфекции Helicobacter pylori: мейнстрим и новации // Российский журнал гастроэнтеролии, гепатолии, колопроктологии. 2017. № 27(4). С. 4-21
Review
For citations:
Bojko E.N., Denisenko N.P., Grishina E.A., Ryzhikova K.A., Sozaeva Zh.A., Sizova Zh.M., Panteleeva L.R., Belyakova G.A., Sychev D.A. THE INFLUENCE OF GENE POLYMORPHISMS СУР2С19 ON THE EFFECTIVENESS OF ERADICATION THERAPY OF H. PYLORI. Experimental and Clinical Gastroenterology. 2018;(6):160-163. (In Russ.)
Views:
318
Email this article 